

**PATENT COOPERATION TREATY**  
**PCT**  
**THIRD PARTY OBSERVATION**  
**(PCT Administrative Instructions Part 8)**

Applicant's or agent's file reference 0614-00145	
International application number PCT/US2022/032601	International filing date (day/month/year) 08 Jun 2022 (08/06/2022)
Applicant MIND MEDICINE, INC.	
Third party observation submitted by Taylor KURTZWEIL	Observation submitted on behalf of Porta Sophia Psychedelic Prior Art Library
Date of submission(day/month/year) 06 Jun 2023 (06/06/2023)	Language of observation English

**Basis and contents of observation**

1. The observation is made on the basis of the claims in the international application as filed.
2. The observation comprises:  
References to documents: 3  
Uploaded copies of documents: 2
3. Further explanations:  
Uploaded copies of documents: 0

**Citation # 1(Periodical article) (# uploaded documents:1):**

Author: Olga G Taraschenko, Heather Y Rubbinaccio, Isabelle M Maisonneuve, Stanley D Glick	Title of article: 18- Methoxycoronaridine: a potential new treatment for obesity in rats?	Title of Periodical: Psychopharmacology	Publication Date: 28 Aug 2008 (28/08/ 2008)
Issue Number of Periodical: 201	Publisher of Periodical:	Place of publication:	
Page range of article within periodical: 339-350	ISBN:	ISSN:	
DOI:			
Most relevant passages or drawings: Abstract		Relevant to Claims: See explanation	
Brief explanation of relevance: Relevant to claims 1, 2, 3, 5, 6, 7, 8, 10, 11  From abstract: "Acute administration of 18-MC (10–40 mg/kg i.p.) reduced operant responding for sucrose and decreased ad libitum ingestion of sucrose, saccharin, and saline. The highest dose of 18-MC also reduced consumption of water when palatable fluids were not available. In rats having unlimited access to sucrose (30%), chronic treatment with 18-MC (20 mg/kg i.p.) prevented sucrose-induced increases in body weight, decreased fat deposition, and reduced consumption of sucrose while not altering food intake."			

**Citation # 2(Periodical article) (# uploaded documents:1):**

Author: Stanley D Glick, Isabelle M Maisonneuve, Karen K Szumlinski	Title of article: 18- Methoxycoronaridine (18-MC) and Ibogaine Comparison of Antiaddictive Efficacy, Toxicity, and Mechanisms of Action	Title of Periodical: Annals of the New York Academy of Science	Publication Date: Sep 2000 (09/2000)
Issue Number of Periodical: Volume 914 Issue 1	Publisher of Periodical:	Place of publication:	
Page range of article within periodical: 369-386	ISBN:	ISSN:	
DOI:			
Most relevant passages or drawings: Pgs 371, 382, Fig 2		Relevant to Claims: 11, 12, 13, 15	
Brief explanation of relevance: From page 371: "The acute intraperitoneal (ip) administration of either ibogaine or 18-MC, 15 min prior to testing, dose-dependently decreased the self-administration of morphine, cocaine, nicotine, and alcohol in rats." Relevant to claims 11, 12, 13, 15  Figure 2: Relevant to claims 11, 12, 13, 14, 15  From page 382: "In conclusion, 18-MC is a novel iboga alkaloid congener, derived from the putative antiaddictive agent, ibogaine, that may potentially serve as a safe and effective treatment for multiple forms of drug abuse." Relevant to claims 11, 12, 13			

**Citation # 3(Web page) (# uploaded documents:0):**

Author: Mind Medicine, Inc.	Title of Page Or Article: A Study to Assess 18-Methoxycoronaridine (18-MC HCl) in Healthy Volunteers		
URL: <a href="https://clinicaltrials.gov/ct2/show/NCT04292197">https://clinicaltrials.gov/ct2/show/NCT04292197</a>			
DOI:			
Name of Website: ClinicalTrials.gov	Publication Date: 03 Mar 2020 (03/03/2020)	Retrieval Date: 01 Feb 2023 (01/02/2023)	
Most relevant passages or drawings: Study Description	Relevant to Claims: 1, 4, 9, 16		
Brief explanation of relevance: From Study Description: "The primary objective of this study is to assess the safety and tolerability of a single day dosing and a separate multiple day dosing of 18-MC HCl administered orally, each part of the study having a different set of healthy male and female volunteers." Relevant to claims 1, 4, 9, 16			